Skip to main content
Top
Published in: Supportive Care in Cancer 2/2015

01-02-2015 | Original Article

Improving hospital performance in the treatment of febrile neutropenia

Authors: Barry Meisenberg, Jan Clemons, John Ness, Nancy Faust, Mary Clance

Published in: Supportive Care in Cancer | Issue 2/2015

Login to get access

Abstract

Purpose

Febrile neutropenia (FN) remains a common and dangerous complication of cancer treatment. Guidelines from the Infectious Disease Society of America urge initiating antibiotics within 2 h of presentation. We reviewed our institution’s performance to identify areas of needed improvement and to design performance improvement steps.

Methods

FN management was deconstructed into discrete tasks. Experienced practitioners estimated appropriate time allowance for each task. Cycle time analysis data on a baseline cohort (baseline group) identified causes and loci of delay. Based on these data, new processes to bypass roadblocks for timely therapy were introduced. Performance monitoring continued as these changes were implemented (the transitional group) and for 20 months thereafter (the post-intervention group).

Results

Sixty-nine episodes of FN were identified. Ten distinct improvement steps were implemented. Median time to antibiotics was reduced from 252 min, to 188 min and 118 min for the baseline, transitional, and post-intervention groups, respectively (p = 0.0002 for the baseline vs. the post-intervention group comparison). Variability was reduced with the inter-quartile range falling from 174 min (baseline) to 65 min (post-intervention). Despite improvement, there were persisting episodes of delays, due to competing priorities from other patients or decisions to postpone infusion of antibiotics until patients had been admitted. Standardized order sets eliminated improper antibiotic choices as a source of error.

Conclusions

Improvements in the management of FN can be accomplished and sustained by the focused study of performance of individual tasks, the design of streamlined processes by practitioners, and the ongoing review of performance with feedback to clinical departments.
Literature
1.
go back to reference Caggiano V, Weiss RV, Rickert TW, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924PubMedCrossRef Caggiano V, Weiss RV, Rickert TW, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924PubMedCrossRef
2.
go back to reference Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266PubMedCrossRef Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266PubMedCrossRef
3.
go back to reference Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed
4.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer; 2010 update by the Infectious Disease Society of America. Clin Infect Dis 52(4):e56–e93PubMedCrossRef Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer; 2010 update by the Infectious Disease Society of America. Clin Infect Dis 52(4):e56–e93PubMedCrossRef
5.
go back to reference Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRef
6.
go back to reference Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for indentifying low-risk febrile neutropenic patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for indentifying low-risk febrile neutropenic patients. J Clin Oncol 18:3038–3051PubMed
7.
go back to reference Clarke RT, Warnick J, Stretton K, Littlewood TJ (2011) Improving the immediate management of neutropenic sepsis in the UK: lessons form a national audit. Brit J Haematol 153:773–779CrossRef Clarke RT, Warnick J, Stretton K, Littlewood TJ (2011) Improving the immediate management of neutropenic sepsis in the UK: lessons form a national audit. Brit J Haematol 153:773–779CrossRef
8.
go back to reference Burry E, Punnet A, Mehta A, Thull-Freedman J, Robinson L, Gupta S (2012) Identification of Educational and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: a quality improvement initiative. Pediatr Blood Cancer 59:431–435PubMedCrossRef Burry E, Punnet A, Mehta A, Thull-Freedman J, Robinson L, Gupta S (2012) Identification of Educational and infrastructural barriers to prompt antibiotic delivery in febrile neutropenia: a quality improvement initiative. Pediatr Blood Cancer 59:431–435PubMedCrossRef
9.
go back to reference Szwajcer D, Czaykowski P, Turner D (2011) Assessment and management of febrile neutropenia in emergency departments within a regional health authority-a benchmark analysis. Curr Oncol 18:280–284PubMedCentralPubMedCrossRef Szwajcer D, Czaykowski P, Turner D (2011) Assessment and management of febrile neutropenia in emergency departments within a regional health authority-a benchmark analysis. Curr Oncol 18:280–284PubMedCentralPubMedCrossRef
10.
go back to reference Nirenberg A, Mulhearn L, Lin S, Larson E (2004) Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Oncol Nurs Forum 31:711–715PubMedCrossRef Nirenberg A, Mulhearn L, Lin S, Larson E (2004) Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Oncol Nurs Forum 31:711–715PubMedCrossRef
11.
go back to reference Wu AW, Kipshutz AKM, Pronovost PJ (2008) Effectiveness and efficiency of root cause analysis in medicine. JAMA 299:685–687PubMedCrossRef Wu AW, Kipshutz AKM, Pronovost PJ (2008) Effectiveness and efficiency of root cause analysis in medicine. JAMA 299:685–687PubMedCrossRef
12.
go back to reference Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87:139–145PubMedCrossRef Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA (2008) Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 87:139–145PubMedCrossRef
13.
go back to reference Baltic T, Schlosser E, Bedell MK (2002) Neutropenic fever: one institution’s quality improvement project to decease time from patient arrival to initiation of antibiotic therapy. Clin J Oncol Nurs 6:337–340PubMedCrossRef Baltic T, Schlosser E, Bedell MK (2002) Neutropenic fever: one institution’s quality improvement project to decease time from patient arrival to initiation of antibiotic therapy. Clin J Oncol Nurs 6:337–340PubMedCrossRef
Metadata
Title
Improving hospital performance in the treatment of febrile neutropenia
Authors
Barry Meisenberg
Jan Clemons
John Ness
Nancy Faust
Mary Clance
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2377-y

Other articles of this Issue 2/2015

Supportive Care in Cancer 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine